BIAL appoints Pierluigi Antonelli as Non-Executive Board Member
BIAL, a hundred-year-old innovation-driven biopharmaceutical company focused on neurology, has announced the appointment of Pierluigi Antonelli, Fresenius Management Board member and Chairman & CEO of Fresenius Kabi, as a non-executive member of its Board of Directors.
Antonio Horta-Osorio, Chairman of BIAL, said: "Pierluigi Antonelli has developed an outstanding professional career in the pharmaceutical and healthcare sector. We are very happy to welcome him to BIAL’s Board of Directors and we are sure we will benefit from his vast experience, further enhancing the Board's capabilities and bringing deep market knowledge.”
Pierluigi Antonelli stated, "After many years in leadership positions in some of the largest companies in the industry, it is clear to me the remarkable path that BIAL has achieved in its 100 years of history. This company clearly represents resilience, strategy, and research capabilities. It is with great satisfaction and a sense of challenge that I accepted to join BIAL’s Board, and I am excited to contribute to the company's ongoing scientific advancements and bringing innovative medicines to the market."
Pierluigi Antonelli has been working in the pharmaceutical industry over the last 25 years having experiences in Life Sciences, Biologics and Generic Drugs sectors. In his previous position, he served as CEO of Angelini Pharma and held senior positions at companies such as Novartis Oncology, Sandoz, Merck & Co, and Bristol-Myers Squibb in the United States and Europe
Pierluigi Antonelli holds an MBA from Kellogg School of Management in the United States and a degree in Economics from the Libera Università Internazionale degli Studi Sociali in Italy.
